You are here: Industry Insights > SCB-2019

News List

Clover Biopharmaceuticals begins Covid-19 vaccine booster trial Pharmaceutical-Technology
November 29, 2021
Clover Biopharmaceuticals has begun a Phase II clinical trial to assess its Covid-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a heterologous booster shot in people who received an initial vaccine regimen.
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine prnewswire
September 13, 2021
Clover Biopharmaceuticals, Ltd. (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that its wholly-owned subsidiary...
Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate prnasia
July 06, 2021
Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, today announced the completion of ...
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate prnasia
June 30, 2021
Clover and Dynavax today announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials worldpharmanews
June 29, 2020
GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials.